Brief: Travere Therapeutics Announces FDA Acceptance Of SNDA For FILSPARI® (Sparsentan) In FSGS
15/05/2025 21:06
May 15 (Reuters) - Travere Therapeutics Inc TVTX.O: TRAVERE THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF SNDA FOR FILSPARI® (SPARSENTAN) IN FSGS TRAVERE THERAPEUTICS INC - PDUFA TARGET ACTION DATE SET FOR JANUARY 13, 2026 TRAVERE THERAPEUTICS INC - FILSPARI COULD BE FIRST FDA-APPROVED TREATMENT FOR FSGS Source text: ID:nBw3cJ84da Further company coverage: TVTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule